Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases.

Thymmune’s machine learning-enabled thymic engineering platform allows for the mass production of iPSC-derived thymic cells to restore immune function through a less invasive approach that can be replicated at high quality at scale. Based on decades of research on the thymus gland, Thymmune’s platform has the potential to transform immunology by developing novel therapies for patients with a range of immune system disorders and even address the biology of immune decline for healthier aging.

In July 2026, United Therapeutics Corporation acquired Thymmune Therapeutics.